Pharmacy Innovations has recalled numerous injectable, ophthalmic (eye), and inhalation drugs due to a lack of assurance of sterility. An FDA inspection revealed insanitary conditions at the manufacturing facility in Erie, Pennsylvania, which could compromise the safety of these sterile medications. The recall covers a wide range of compounded products, including hormones (testosterone, progesterone), vitamins (Methylcobalamin, Vitamin D3), and specialty treatments like Semaglutide. While no incidents or injuries have been reported, medications administered via injection or applied to the eyes must be sterile to prevent serious illness.
Using medications that lack sterility assurance poses a serious risk of infection. Because these drugs are injected into the body or applied directly to the eyes, any contamination could bypass natural defenses and lead to severe, potentially life-threatening medical complications.
You have 2 options:
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.